XML 74 R67.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Parenthetical) (Details) - United Therapeutics Corporation - Collaboration and License Agreement
$ in Millions
1 Months Ended
Dec. 31, 2022
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]  
Total anticipated cash flows $ 722.3 [1]
Manufacturing Services  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]  
Total anticipated cash flows 722.3
Manufacturing Services and Product Sales  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]  
Allocated transaction price 220.8
Manufacturing Services and Product Sales | Transaction Price For The Contractual Obligations  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]  
Total anticipated cash flows 120.0
Next-Gen R&D Services | Transaction Price For The Performance Obligations  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]  
Total anticipated cash flows $ 602.3
[1] The total anticipated cash flow includes a transaction price of $120.0 million for the contractual obligations under the CSA for the Manufacturing Services and Product Sales and the Next-Gen R&D Services performance obligations and $602.3 million for future supply of Tyvaso DPI over the remaining term of the CSA.